Antibodies that bind interleukin-2 and uses thereof

US12234285B2 · kind B2 · utility

Assignees

• XOMA (US) LLC · US
• MUSC Foundation for Research Development · US

Inventors

• Marina Roell · Concord, US
• Mark Rubinstein · Charleston, US
• Hassan Issafras · Berkeley, US
• Llewelyn Lao · San Francisco, US
• Ou Li · San Francisco, US
• Daniel Bedinger · Vacaville, US
• Kristin Camfield Lind · Oakland, US
• Agnes Choppin Holmes · Mountain View, US
• Toshihiko Takeuchi · Oakland, US
• Lauren Schwimmer · Alameda, US
• Hoa Giang · Alameda, US
• Amer M. Mirza · San Francisco, US
• Kirk W. Johnson · Berkeley, US

Key dates

• Filing date: Dec 4, 2020
• Grant date: Feb 25, 2025
• Expiry date: Nov 29, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.